SEOUL, SOUTH KOREA | January 27, 2026 — Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced a strategic exclusive distribution partnership with Mexico-based Laboratorios Sanfer to commercialize efpeglenatide, Korea’s first domestically developed GLP-1 class obesity and metabolic disease therapy, along with Hanmi’s Dapalon Family diabetes treatments. Under the agreement, Hanmi will supply finished pharmaceutical products, while Sanfer will manage regulatory approvals, marketing, distribution, and sales in Mexico, marking a significant step in Hanmi’s global expansion strategy for metabolic disease therapeutics.
Science Significance
Scientifically, the agreement highlights the growing global importance of GLP-1 receptor agonists in addressing obesity and metabolic disorders. Efpeglenatide is designed to improve weight management and glycemic control by targeting key metabolic pathways involved in appetite regulation and glucose homeostasis. As obesity and diabetes increasingly coexist as chronic, interrelated conditions, therapies capable of addressing both disease drivers are gaining clinical relevance. Hanmi’s continued development of efpeglenatide, including combination strategies with SGLT-2 inhibitors and metformin, reflects a science-driven approach to expanding therapeutic utility across the metabolic disease spectrum.
Regulatory Significance
From a regulatory standpoint, the partnership places Sanfer in charge of local regulatory submissions and approvals in Mexico, a market with stringent but evolving pharmaceutical oversight. Hanmi has already completed a regulatory application for efpeglenatide in South Korea and secured IND approval for a Phase 3 combination therapy trial in early 2026, demonstrating progress under established GxP-compliant development frameworks. Successful navigation of Mexico’s regulatory pathways will require alignment with Good Manufacturing Practice (GMP), pharmacovigilance obligations, and post-marketing surveillance, reinforcing the importance of compliant cross-border supply and lifecycle management.
Business Significance
Advertisement
Commercially, the deal significantly strengthens Hanmi’s international footprint in one of the world’s fastest-growing obesity and diabetes markets. Mexico’s high prevalence of obesity and diabetes creates strong demand for innovative metabolic therapies, and Sanfer’s extensive Latin American distribution network provides Hanmi with an established route to market. For Sanfer, the agreement expands its metabolic disease portfolio with globally competitive GLP-1 and diabetes products, while for Hanmi it validates the global scalability of its R&D and formulation capabilities. The partnership also lays the groundwork for future collaborations across additional metabolic indications and products.
Patients’ Significance
For patients in Mexico, the agreement has the potential to improve access to innovative obesity and diabetes treatments in a healthcare system under pressure from rising chronic disease burden. With obesity prevalence exceeding one-third of the population and diabetes rates among the highest globally, therapies like efpeglenatide could support earlier intervention, improved disease management, and reduced long-term complications. Broader access to GLP-1–based therapies may also help address gaps where lifestyle interventions alone are insufficient, offering patients clinically proven pharmacologic options.
Policy Significance
At the policy level, the partnership aligns with Mexico’s increasing emphasis on strengthening chronic disease management and standardizing healthcare delivery. Governments worldwide are prioritizing access to effective metabolic disease treatments to mitigate long-term healthcare costs associated with obesity-related complications. Cross-border pharmaceutical partnerships such as this one support technology transfer, local regulatory engagement, and supply chain resilience, contributing to national public health objectives while ensuring adherence to international quality and safety standards.
The exclusive distribution agreement between Hanmi Pharmaceutical and Laboratorios Sanfer represents a meaningful milestone in the global commercialization of GLP-1–based metabolic therapies. By combining Hanmi’s R&D-driven product portfolio with Sanfer’s regulatory and commercial expertise in Latin America, the partnership advances compliant market entry for efpeglenatide while addressing urgent public health needs. For the cGxP.wire audience, this development underscores how pharma partnerships, grounded in regulatory readiness and GMP-aligned supply strategies, are shaping global access to next-generation obesity and diabetes treatments.
Source: Hanmi Pharmaceutical press release
